S. Lupovitch

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Khalid Yusoff, Frederick M. Costello, Martin O'Donnell, 2017, Lancet.

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

R. D. Jenkins, Andreas Wilke, A. Capucci, 2022, Clinical Research in Cardiology.

Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.

R. D. Jenkins, A. Capucci, G. Lip, 2020, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Biocompatibility Studies of Hemoperfusion Systems for Liver and Kidney Support

S. Sideman, J. Brandes, E. Hoffer, 1978 .

Assessment of small-diameter aortic mechanical prostheses: physiological relevance of the Doppler gradient, utility of flow augmentation, and limitations of orifice area estimation.

R. Kerber, A. Yoganathan, R. Lang, 1998, Circulation.

Preparation of a biocompatible albumin-coated ion exchange resin for bilirubin removal from the blood of jaundiced newborns.

S. Sideman, J. Brandes, S. Lupovitch, 1983, Journal of biomedical materials research.

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

James S. Crenshaw, R. D. Jenkins, David W. Smith, 2023, EClinicalMedicine.

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.

Zahid Ali Zafar, Mark A. Kutner, J. Neutel, 2023, JAMA.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.